Rigel Pharmaceuticals Inc's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Rigel Pharmaceuticals Inc's ROA in the third quarter of 2026?
Rigel Pharmaceuticals Inc achieved a return on average assets (ROA) of 59.56 % in its third quarter of 2026, this is above RIGL's average return on assets of -27.02%.
Rigel Pharmaceuticals Inc assets over the 12 months ending in its third quarter of 2026 are valued at $516 million

ROA decreased relative to the period ending Jun 30 2026, due to the decline in net income.

However, within the Healthcare sector 15 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 38, from total ROA ranking in the second quarter of 2026 at 46.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Total Assets Change	115.98 %	152.04 %	186.75 %	214.52 %	73.96 %
Y / Y Net Income Change	-52.74 %	-71 %	-24.39 %	1769.22 %	124.62 %
Net Income (TTM) in million	307	322	364	367	113
Return On Assets (TTM)	59.56 %	72.27 %	99.28 %	128.91 %	57.47 %
RIGL's Total Ranking	# 38	# 46	# 62	# 66	# 172
Total Assets (TTM) in million	524	521	505	514	243
Seq. Total Assets Change	0.53 %	3.26 %	-1.75 %	111.76 %	17.32 %
Seq. Net Income Change	-23.74 %	99.79 %	-96.77 %	860.81 %	-53.2 %

RIGL's 5 Years Annual ROA >> Back to RIGL Management Effectiveness >> Compare RIGL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 7
Sector	# 16
Overall	# 55

Return On Assets Statistics
High	Average	Low
128.91 %	-27.02 %	-92.95 %
(Dec 31 2025)		(Mar 31 2018)

Financial Statements
Rigel Pharmaceuticals Inc's Assets	$ 524 million	RIGL's Balance sheet
Rigel Pharmaceuticals Inc's Income	$ 13 million	Quarterly RIGL's Income Statement
RIGL's Income by Division		See RIGL's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	214.52 %	-68.43 %	285.15 %	-19.75 %	51.6 %
Total Assets in million	514	163	517	134	167
Y / Y Net Income Change	1999.08 %	-	-	-	-
Net Income in million	367	17	-25	-59	-18
Annual Return On Assets	71.46 %	10.71 %	-4.85 %	-43.62 %	-10.71 %

RIGL's 5 Years Annual ROA >> Back to RIGL Management Effectiveness >> Compare RIGL ROA to its Competitors

Comment on RIGL's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 71.46 % compared to prior year, due to annual net income growth of 1999.08 % to $367.02 million, while value of Rigel Pharmaceuticals Inc's overall assets grew just by 214.52 % to $513.59 million, compared to $513.59 a year before.

More Return On Assets Ratios
RIGL's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RIGL's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RIGL's Competitors
Subscribers only: Roa for Rigel Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Assets for RIGL's Customers

You may also want to know
RIGL's Roi	RIGL's Inventory Turnover Ratio	RIGL's Growth Rates	RIGL's Dividend Comparisons
	RIGL's Profitability Ratios	RIGL's Asset Turnover Ratio	RIGL's Dividend Growth
RIGL's Roe	RIGL's Valuation Ratios	RIGL's Financial Strength Ratios	RIGL's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Exelixis Inc	63.88 %
Rigel Pharmaceuticals Inc	59.56 %
Alnylam Pharmaceuticals Inc	46.08 %
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %

Date modified: 2026-11-09T06:44:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.